ACASTI PHARMA INC. (?ACST?)
BULLETIN TYPE: Prospectus-Share Offering, Private Placement-Brokered
BULLETIN DATE: February 7, 2018
TSX Venture Tier 2 Company
Prospectus-Share Offering
The Company's Prospectus dated December 21, 2017, was filed with and accepted by TSX Venture Exchange and a registration statement relating to the offering was filed with the Securities and Exchange Commission (SEC) on December 19, 2017 and the SEC issued a notice of effectiveness of that offering dated December 19, 2017.
Underwriters: The Benchmark Company, LLC and Dawson James Securities, Inc.
Offering: 9,900,990 common shares at a price of US$1.01 per share and warrants to purchase 8,910,891 common shares at an exercise price of US$1.26 per share during a period of 5 years
Offering Price: US$1.01 per common share
Warrant Exercise Price: US$1.26 per Share during a period of five years.
Underwriters? Fee: 7% of the gross proceeds in cash and non-transferable broker warrants to purchase that number of common shares that is equal to 5% of the number of shares issued pursuant to the offering at the exercise price of US$1.26 per share during a period of 5 years following the closing date.
Over-Allotment Option: The underwriters have been granted an over-allotment option, exercisable for a period of 30 days following the date of the prospectus, to purchase an additional number of up to 1,100,110 common shares and up to 990,099 warrants.
The Company announced the closing of the prospectus offering by news release dated December 27, 2017 and the exercise of the over-allotment option by news release dated January 22, 2018. The aggregate gross proceeds received by the Company pursuant to the prospectus offering were approximately US$9,531,540 (9,437,169 common shares at US$1.01 per share) including the exercise of the over-allotment option.
The common shares and warrants offered pursuant to the above-mentioned prospectus have not been and will not be qualified for distribution pursuant to a prospectus filed with the securities regulatory authorities in any of the provinces or territories of Canada and were not offered or sold in Canada except on a private placement basis pursuant to an exemption from the prospectus requirements of applicable Canadian securities laws. Any such common shares and warrants sold in Canada were sold pursuant to a confidential offering memorandum which supplemented the disclosure of the final prospectus forming part of the registration statement. See the bulletin ?Private Placement-Brokered? below for the common shares and warrants sold in Canada concurrently to the prospectus offering.
Private Placement-Brokered
TSX Venture Exchange has accepted for filing documentation with respect to a Brokered Private Placement announced on December 21, 2017:
Number of Shares: 1,230,000 common shares
Purchase Price: US$1.01 per Common Share
Warrants: 1,107,000 warrants to purchase 1,107,000 Common Shares
Warrant Exercise Price: US$1.26 for a period of 5 years following the closing date.
Number of Placees: 15 Placees
Intermediaries? fees: Arm?s length intermediaries received an aggregate of US$62,114.50 in cash and 61,500 non-transferable broker warrants to purchase 61,500 common shares at an exercise price of US$1.2625 during a period of 5 years following the closing date.
The Company has confirmed the closing of the above-mentioned Private Placement pursuant to a news release dated December 27, 2017.
ACASTI PHARMA INC. (< ACST >)
TYPE DE BULLETIN : Emission d?actions par prospectus, Placement prive par l?entremise d?un courtier
DATE DU BULLETIN : Le 7 fevrier 2018
Societe du groupe 2 de TSX croissance
Emission d?actions par prospectus
Le prospectus de la societe date du 21 decembre 2017 a ete depose et accepte par la Bourse de croissance TSX et une declaration d?inscription ete depose a la Securities and Exchange Commission (SEC). La SEC a emis un avis de prise d?effet date du 19 decembre 2017 relativement a ce placement.
Preneurs fermes : The Benchmark Company, LLC et Dawson James Securities, Inc.
Offre : 9 900 990 actions ordinaires souscrites au prix de 1,01 $ US par action et des bons de souscription permettant de souscription 8 910 891 actions ordinaires au prix d?exercice de 1,26 $ US par actions pendant une periode de 5 ans.
Prix de l?offre: 1,01 $ US par action ordinaire
Prix d?exercice des bons: 1,26 $ US par action pendant une periode de cinq ans.
Commission aux preneurs
fermes : 7 % du produit brut en especes et des bons de courtier non-transferables permettant de souscrire un nombre d?actions correspondant a 5 % du nombre d?actions emises en vertu du placement au prix d?exercice de 1,26 $ US par action pendant une periode de 5 ans suivant la date de cloture.
Option d?attribution
excedentaire : Les preneurs fermes ont recu une option pour attributions excedentaires, applicable pendant une periode de 30 jours suivant la date du prospectus, visant l?acquisition d?un nombre maximum additionnel de 1 100 110 actions ordinaires et 990,099 bons de souscription.
La societe a confirme la cloture de l?appel public a l?epargne dans le communique de presse du 27 decembre 2017 et l?exercice de l?option d?attribution excedentaire dans le communique de presse du 22 janvier 2018. Le produit brut recu par la societe en vertu de l?appel public a l?epargne est environ 9 531 540 $ US (9 437 169 actions au prix de 1,01 $ US par action) incluant l?exercice de l?option d?attribution excedentaire.
Les actions ordinaires et les bons de souscription offerts aux termes du prospectus susmentionne n'ont pas ete ni ne seront distribues aux termes d'un prospectus depose aupres des autorites en valeurs mobilieres des provinces ou des territoires du Canada et n'ont pas ete offerts ou vendus au Canada sauf sur une base de placement prive en vertu d'une dispense de prospectus des lois sur les valeurs mobilieres canadiennes applicables. Ces actions ordinaires et bons de souscription vendus au Canada ont ete vendus aux termes d'une notice d'offre confidentielle qui completait la divulgation du prospectus faisant partie de la declaration d'inscription a la SEC. Voir le bulletin <Placement prive par l?entremise d?un courtier> ci-dessous pour les actions ordinaires et les bons de souscription vendus au Canada.
Placement prive par l?entremise d?un courtier
Bourse de croissance TSX a accepte le depot de la documentation en vertu d?un placement prive par l?entremise d?un courtier annonce le 21 decembre 2017:
Nombre d?actions : 1 230 000 actions ordinaires
Prix : 1,01 $ US par action ordinaire
Bons de souscription : 1 107 000 bons de souscription permettant de souscrire a 1 107 000 actions ordinaires
Prix d?exercice des bons : 1,26 $ US pendant une periode de 5 ans suivant la cloture
Nombre de souscripteurs : 15 souscripteurs
Frais d?intermediation : Des intermediaires sans lien de dependance ont recu un total de 62 114,50 $ US en especes et 61 500 bons de courtiers non-transferables permettant de souscrire 61 500 actions ordinaires au prix d?exercice de 1,26 $ US pendant une periode de 5 ans suivant la date de cloture.
La societe a confirme la cloture du placement prive precite dans le cadre d?un communique de presse date du 27 decembre 2017.
__________________________________
|
|
